Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2014', provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6 Therapeutics Development 7 Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 7 Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 8 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 9 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 13 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 14 Gilead Sciences, Inc. 14 Human Stem Cells Institute 15 Juventas Therapeutics, Inc. 16 Lacer, S.A. 17 Nuo Therapeutics, Inc. 18 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ALD-201 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Biglycan Therapy for Cardiovascular Diseases - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Cryocell - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 JVS-100 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LA-419 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ranolazine ER - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 38 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2014 7 Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H2 2014 14 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2014 15 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H2 2014 16 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H2 2014 17 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H2 2014 38 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2014 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.